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Abstract 17 
Neonates are at a high risk of infection, but vaccines are less effective in this age group; 18 
tailored adjuvants could potentially improve vaccine efficacy. Increased understanding 19 
about danger sensing by the innate immune system has led to the rational design of novel 20 
adjuvants. But differences in the neonatal innate immune response, for example to TLR 21 
agonists, can reduce the efficacy of these adjuvants in early life. We therefore targeted 22 
alternative danger sensing pathways, focusing on a range of compounds described as 23 
inflammasome agonists, including Nanoscale SiO2 (NanoSiO2), Calcium pyrophosphate 24 
dihydrate (CPPD) crystals and muramyl tripeptide (M-Tri-DAP), for their ability to act as 25 
adjuvants. In vitro these compounds induced an interleukin 1-beta (IL-1β) response in the 26 
macrophage-like cell line THP1. In vivo, adult CB6F1 female mice were immunised 27 
intramuscularly with H1N1 influenza vaccine antigens in combination with NanoSiO2, CPPD 28 
or M-Tri-DAP and subsequently challenged with H1N1 influenza (A/England/195/2009). The 29 
adjuvants boosted anti-haemagglutinin IgG and IgA antibody levels. Both adult and neonatal 30 
animals that received NanoSiO2 adjuvanted vaccines lost significantly less weight and 31 
recovered earlier after infection than control animals treated with antigen alone. 32 
Administration of the adjuvants led to an influx of activated inflammatory cells into the 33 
muscle, but little systemic inflammation measured by serum cytokines. Blocking IL-1β or 34 
caspase 1 in vivo had little effect on NanoSiO2 adjuvant function, suggesting it may work 35 
through other pathways than the inflammasome. Here we demonstrate that NanoSiO2 can 36 
act as an adjuvant and is effective in early life. 37 
  38 
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Importance 39 
Vaccines can fail to protect the most at-risk populations, including the very young, elderly 40 
and immunocompromised. There is a gap in neonatal immunity between the waning of 41 
maternal protection and routine infant immunisation schedules, exacerbated by the failure 42 
of vaccines to work in the first months of life. One approach is to design age-specific 43 
formulations, with more effective adjuvants, based on our understanding of the nature of 44 
the neonatal immune response. We chose to target the inflammasome, a molecular 45 
complex capable of detecting infection and cell damage and of triggering IL-1β driven 46 
inflammation. We screened a range of compounds in vitro and in vivo and identified three 47 
lead candidates: NanoSiO2, CPPD and M-Tri-DAP. Of these, NanoSiO2 was the most 48 
effective and boosted the anti-influenza response in both adult and neonatal mice. This is 49 
important for the development of age-specific vaccines, designed using our knowledge of 50 
the neonatal immune response.  51 
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Introduction 52 
Infants bear the brunt of mortality and morbidity from infectious diseases, with 36% of the 53 
annual 3.3 million deaths in newborn children caused by infections (1). Influenza infection is 54 
especially prevalent in early life, with high rates of hospitalisation (50–100/10,000 55 
children/year (2)). Due to the immaturity of the immune response, vaccines that are 56 
otherwise protective in adults are ineffective in early life (3). To counteract this, one 57 
approach is to develop adjuvants that can boost the immunogenicity of vaccines in infants 58 
(4). Whilst there are a range of adjuvant formulations that are currently included in licensed 59 
vaccines (5), the unique nature of the neonatal immune response means that targeted 60 
approaches are required. Many of the next-generation adjuvants, for example GLA (6), a 61 
lipolysaccharide mimic, target the Toll-like receptors (TLR), but the functionality of TLR 62 
receptors is diminished during early life (7). In multiple studies, the production of the 63 
cytokine Tumour Necrosis Factor (TNF) after exposure to TLR ligands has been shown to be 64 
age-related (8, 9). 65 
However, TLR are not the only pattern recognition receptors and it may be that targeting 66 
other receptors can boost neonatal responses, for example the dectin-1 ligand curdlan has 67 
been shown to activate neonatal dendritic cells (10). The inflammasomes are another family 68 
of danger sensing receptors (11) that respond to a wide range of cellular damage and 69 
infection, leading to the formation of a caspase 1 complex, which can catalyse the cleavage 70 
of pro-interleukin 1-beta (IL-1β) into the active form. Relatively little is known about 71 
inflammasomes in early life, but targeting these complexes to induce IL-1β release may be 72 
an effective approach to improve vaccine immunogenicity. In a number of studies, IL-1β has 73 
been shown to be important in the immune response to adjuvanted vaccines, having a role 74 
in neutrophil recruitment (12) and antibody production (13), and it has been used directly as 75 
an adjuvant (14). 76 
Inflammasomes are triggered by a range of compounds (11) and particle size appears to be 77 
a key factor in triggering them (15). A range of nanoparticles have been associated with 78 
various forms of inflammasome-mediated inflammation, including Nanoscale silicon dioxide 79 
(NanoSiO2) (16), Calcium pyrophosphate dihydrate (CPPD) (17), monosodium urate (MSU) 80 
(18) and alum (19). Other compounds including γ-d-glutamyl-meso-diaminopimelic acid (iE-81 
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DAP) and N-acetylmuramyl-L-alanyl-D-isoglutamine (MDP) (20) have also been described as 82 
NOD receptor agonists, leading to activation of the inflammasome. The concept behind the 83 
current study was to exploit the inflammation induced by these compounds for a beneficial 84 
improvement of the response to vaccine antigen. To test the hypothesis that microparticles 85 
can act as adjuvants, we screened a range of compounds in vivo and in vitro for their ability 86 
to induce an IL-1β response and to improve the immune response to influenza antigens. Of 87 
the compounds tested, NanoSiO2, CPPD and M-Tri-DAP led to a greater anti-influenza 88 
response, and NanoSiO2 was the most effective. When neonatal mice were immunised with 89 
NanoSiO2 and antigen there was significantly less weight loss after influenza challenge than 90 
antigen alone  91 
  92 
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Materials and methods  93 
Experimental Adjuvants 94 
The compounds tested as adjuvants (IE-DAP, M-Tri-DAP, MDP, Alum Crystals, MSU, CPPD 95 
and NanoSiO2) were obtained from Invivogen (France). Compounds were resuspended in 96 
H2O. MF59 was provided by GSK Vaccines (Sienna, Italy). 97 
In vitro cell stimulations  98 
THP-1 cells were grown in RPMI with 10% FCS, L-glutamine and penicillin/streptomycin. 99 
THP-1 cells were differentiated into phagocyte-type cells by seeding into new tissue culture 100 
plates, supplementing with 20 ng/ml PMA, and incubating for 24 hours before being rested 101 
for a further 24 hours (adapted from (21)). To generate bone marrow-derived macrophages 102 
(BMDM), adult mouse femurs were first harvested and flushed. Flushed bone marrow was 103 
then pelleted via centrifugation before red cell lysis using ACK lysis buffer (Lonza). Cells were 104 
resuspended and seeded at required density in bone-marrow macrophage media consisting 105 
of 49% w/v DMEM, 25% L929 cell derived medium, 25% FBS and 1% penicillin/ streptomycin 106 
supplemented with 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)(Sigma) to 107 
25mM. BMDM cells were stimulated with 1 µg Monophosphoryl Lipid A (MPLA)(Sigma) prior 108 
to adjuvant exposure. Cells were stimulated for 72 hours with adjuvants, and supernatants 109 
collected for IL-1β analysis. 110 
Influenza 111 
H1N1 Influenza (strain A/England/195/2009) was grown in Madin-Darby Canine Kidney 112 
(MDCK) cells, in serum free DMEM supplemented with 1 µg/ml trypsin. H1N1 Influenza 113 
strain (A/England/195/2009) was isolated by Public Health England in the UK, April 2009 114 
(22). The virus was harvested 3 days after inoculation and stored at -80°C. Viral titre was 115 
determined by plaque assay as previously described (23). 116 
Mouse immunization and infection 117 
6–8 week old female CB6F1 mice were obtained from Harlan UK Ltd (Swindon Town, UK) 118 
and kept in specific-pathogen-free conditions in accordance with the United Kingdom's 119 
Home Office guidelines and all work was approved by the Animal Welfare and Ethical 120 
Review Board (AWERB) at Imperial College London. Experiments were designed following 121 
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the ARRIVE guidelines. Neonatal mice were bred in house, from C57BL/6 male and BALB/c 122 
female parents and immunised at d7 of life. Adult mice were immunized intramuscularly 123 
(i.m.) with 50 μl including 0.1 μg purified surface antigens from influenza strain H1N1 124 
A/California/7/2009 (GSK Vaccines, Siena, Italy). Neonatal mice were immunised 125 
intramuscularly with 25 μl in each hind quadriceps and infected 5 weeks later. Adjuvants 126 
were used at the following concentrations in the pilot study 0.5 µg: IE-DAP, M-Tri-DAP, 127 
MDP, 2.5μg: CPPD, 10 μg Alum, MSU, NanoSiO2, in later studies concentrations are as 128 
described in text. For infections, mice were anaesthetized using isoflurane and infected 129 
intranasally (i.n.) with 6x104 PFU of influenza A H1N1 in 100 μl. 130 
In vivo blockade 131 
Intraperitoneal (i.p.) injection of 0.5 mg anti-murine IL-1β antibody B122 (BioXCell) was used 132 
to block IL-1β activity in vivo 24 hours before and 24 hours after immunisation. An 133 
irreversible murine caspase-1 inhibitor molecule, amino acid sequence Acetyl-Tyr-Val-Ala-134 
Asp-Chloromethylketone (Ac-YVAD-cmk) (Sigma), was used to block caspase-1 activity. Ac-135 
YVAD-cmk, reconstituted in sterile H2O, was administered to mice at 10 mg/kg body weight 136 
by i.p. injection in a 500 μl volume 24 hours before and after vaccinations as described 137 
above.  138 
Semi-quantitative antigen-specific ELISA  139 
Antibodies specific to influenza H1N1 were measured using a standardized ELISA. IgG 140 
responses were measured in sera and IgA responses in bronchoalveolar lavage. MaxiSorp 141 
96-well plates (Nunc) were coated with 1 µg/ml H1N1 surface protein, or a combination of 142 
anti-murine lambda and kappa light chain specific antibodies (AbDSerotec, Oxford, UK) and 143 
incubated overnight at 4°C. Plates were blocked with 1% BSA in PBS. Bound IgG was 144 
detected with HRP-conjugated goat anti-mouse IgG (AbD Serotec). Bound IgA was detected 145 
using a biotinylated anti-IgA and a streptavidin-HRP. A dilution series of recombinant murine 146 
IgG or IgA was used as a standard to quantify specific antibodies. TMB with H2SO4 as stop 147 
solution was used to detect the response and optical densities read at 450 nm. 148 
Tissue and cell recovery and isolation 149 
Mice were culled using 100 μl i.p. pentobarbitone (20 mg dose, Pentoject, Animalcare Ltd. 150 
UK) and tissues collected as previously described (24). Blood was collected from carotid 151 
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vessels and sera isolated after clotting by centrifugation. Bronchoalveolar lavage (BAL) was 152 
obtained by inflating the lungs via an intratracheal cannula with PBS. Lungs were removed 153 
and homogenized by passage through 100 μm cell strainers, then centrifuged at 200 x g for 154 
5 minutes. Supernatants were removed and the cell pellet treated with red blood cell lysis 155 
buffer (ACK; 0.15 M ammonium chloride, 1 M potassium hydrogen carbonate, and 0.01 mM 156 
EDTA, pH 7.2) before centrifugation at 200 x g for 5 minutes. The remaining cells were 157 
resuspended in RPMI 1640 medium with 10% fetal calf serum, and viable cell numbers 158 
determined by trypan blue exclusion. 159 
Muscle cells 160 
Cells were isolated from the quadriceps muscle following i.m. injection, as described (25). 161 
The quadriceps muscle was excised from the limb and placed in ice cold DMEM. Muscles 162 
were transferred onto petri dishes and minced using a scalpel and scissors. Dish contents 163 
were washed and transferred into falcon tubes containing modified eagle medium (MEM) 164 
(Gibco). Tissue was resuspended in 2 ml MEM containing 0.05% type II collagenase 165 
(Worthington Biochemical). Tubes were incubated at 37°C with gentle agitation for 30 166 
minutes and cells resuspended in DMEM before filtration through a 40 μm filter cap 167 
(Grenier Bio-one). Isolated cells were counted using a haemocytometer as previously 168 
described before being subjected to flow cytometry. 169 
Cytokine detection 170 
Human and murine IL-1β levels were assessed in BAL by ELISA (R&D systems) following 171 
manufacturer’s instructions. Acute systemic responses to adjuvants in vivo were measured 172 
using a 17-plex Magnetic Screening Luminex Assay kit (R&D systems) according to the 173 
manufacturer’s instructions. 174 
Influenza viral load 175 
Viral load in vivo was assessed by Trizol extraction of RNA from frozen lung tissue disrupted 176 
in a TissueLyzer (Qiagen, Manchester, UK). RNA was converted into cDNA and quantitative 177 
RT-PCR was carried out using bulk viral RNA, for the Influenza M gene and mRNA using 0.1 178 
μM forward primer (5’-AAGACAAGACCAATYCTGTCACCTCT-3’), 0.1 μM reverse primer (5’-179 
TCTACGYTGCAGTCCYCGCT-3’) and 0.2 μM probe (5’-FAM-TYACGCTCACCGTGCCCAGTG-180 
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TAMRA-3’) on a Stratagene Mx3005p (Agilent technologies, Santa Clara, CA, USA). M-181 
specific RNA copy number was determined using an influenza M gene standard plasmid. 182 
Flow cytometry 183 
Live cells were suspended in Fc block (Anti-CD16/32, BD) in PBS-1% BSA and stained with 184 
surface antibodies (Panel 1: Influenza A H1 HA533-541 IYSTVASSL Pentamer R-PE (Proimmune, 185 
Oxford, UK), CD3-FITC (BD, Oxford UK), CD4-APC (BD), CD8-APC Alexa75 (Invitrogen, Paisley, 186 
UK); Panel 2: CD11c-FITC (BD), CD11b-PE (Life Sciences) CD80-APC (eBioscience), MHCII-187 
eflour450 (eBioscience), F4/80-PECy7 (eBioscience) and Ly6G-BV605 (BD)). Analysis was 188 
performed on an LSRFortessa flow cytometer (BD). FMO controls were used for surface 189 
stains. 190 
Statistical Analysis. Calculations as described in figure legends were performed using Prism 191 
6 (GraphPad Software Inc., La Jolla, CA, USA). 192 
  193 
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Results  194 
Screening studies to select inflammasome-targeting adjuvants. 195 
The aim of the study was to investigate the role of putative inflammasome-activating 196 
agonists as adjuvants. We initially screened the compounds using the macrophage-like cell 197 
line THP1. Cells were exposed to 10 μg/ml compound and the IL-1β response measured at 198 
various time points after exposure (Fig 1A). Of the compounds tested, the greatest response 199 
was induced by NanoSiO2, but both CPPD and M-Tri-DAP induced a level greater than that 200 
induced by PBS. A smaller subset of the reagents was then tested in mouse bone marrow 201 
derived macrophages (BMDM). Cells were pre-exposed to MPLA for 2 hours prior to 202 
exposure to NanoSiO2, CPPD or M-Tri-DAP, which were the best performing compounds in 203 
the THP1 studies. Of the compounds tested, only NanoSiO2 induced a significant level of IL-204 
1β (Fig 1B). No IL-1β was detected from BMDM cells exposed to compounds in the absence 205 
of MPLA pre-stimulation.  206 
In a small pilot study, we then screened the same compounds for their effect on in vivo 207 
responses to influenza antigen in adult mice. Mice were immunised with 0.1 µg influenza 208 
surface proteins from CAL7/09 in combination with experimental adjuvants. Adjuvant dose 209 
was based on the levels recommended for in vitro use and were used at the following 210 
concentrations in the pilot study 0.5 µg: IE-DAP, MTri-DAP, MDP, 2.5μg: CPPD, 10 μg Alum, 211 
MSU, NanoSiO2. The dose of protein was chosen as it gives incomplete protection and 212 
therefore the effect of the adjuvant can be observed. Mice were infected intranasally with 213 
H1N1 ENG/195. Unimmunised mice lost weight from day 1 of infection, peaking at 15% 214 
weight loss, and protein alone made a very slight difference to the protective response (Fig 215 
1C data split into two graphs for clarity). Interestingly a number of the adjuvants appeared 216 
to reduce the protective capacity of protein including IE-DAP, M-Tri-DAP, MDP and Alum 217 
Crystals (Fig 1D). NanoSiO2 and CPPD changed the profile of the disease with a more rapid 218 
weight loss, but a faster recovery. CPPD was more protective than antigen alone. To 219 
determine whether the adjuvants boosted immune responses, we measured the H1N1-220 
specific IgG responses in serum at d7 after infection (Fig 1E). Of the compounds tested, 221 
NanoSiO2 gave the highest IgG response. Airway IgA responses, measured in BAL, were 222 
greater after adjuvant administration (Fig 1F), with CPPD and NanoSiO2 both inducing a 223 
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greater response than antigen alone, and MSU and IE-DAP inducing a similar response. 224 
Based on these results, we selected 3 compounds for further study: NanoSiO2 because it 225 
gave a high IL-1β response, altered weight loss dynamic and high antibody response; CPPD 226 
because it gave increased protection and some antibody response; and M-Tri-DAP as it is a 227 
model NOD receptor agonist. 228 
Dose Titration studies 229 
As the compounds are all chemically diverse, we wished to investigate whether there was 230 
an optimum dose of adjuvant. We started by measuring the dose response to NanoSiO2 and 231 
comparing with antigen alone. Mice received a single intramuscular immunisation with 0.1 232 
μg H1N1 and increasing doses of NanoSiO2. The anti-H1N1 IgG response was measured in 233 
serum 28 days after immunisation. The group adjuvanted with 50 μg NanoSiO2 had a 234 
significantly greater IgG response than the groups receiving antigen alone or antigen 235 
adjuvanted with 1 μg NanoSiO2 (p<0.05, Fig 2A). Mice were subsequently challenged with 236 
H1N1 influenza. Mice adjuvanted with 50 μg NanoSiO2 had a lower peak weight loss and 237 
recovered significantly faster than mice immunised with antigen alone (p<0.01, Fig 2B). 238 
Influenza RNA was detectable in the lungs after infection, and there was a trend for less viral 239 
load after immunisation with the highest doses of adjuvant (10 μg or 50 μg) (Fig 2C).. There 240 
was also antigen specific IgA detectable in the BAL of immunised animals (Fig 2D). 241 
Interestingly, there were also H1 influenza-specific CD8+ T cells detectable in the lungs of 242 
adjuvant immunised mice (Fig 2E), but not the mice receiving protein alone. We performed 243 
correlation analysis of weight loss with IgG (Fig 2F), IgA (Fig 2G) and H1 specific CD8+ (Fig 244 
2H). IgG levels were significantly inversely correlated with weight loss, suggesting IgG is 245 
protective against disease. 246 
We performed similar dose titration studies with CPPD and M-Tri-DAP (Fig 3). High dose 247 
CPPD led to a significantly greater H1N1-specific IgG response than antigen alone after 248 
immunisation and prior to infection (p<0.01, Fig 3A). However, there was no difference in 249 
weight loss (Fig 3B) or viral load (Fig 3C) after infection between adjuvanted and protein 250 
alone groups. Unlike NanoSiO2, CPPD did not induce a greater influenza specific CD8+ T cell 251 
response than antigen alone (Fig 3D). There was a trend to increased IgA in the airways of 252 
adjuvanted mice (Fig 3E).  253 
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There was no significant effect of M-Tri-DAP on antibody responses (Fig 3F). However, the 254 
highest dose of adjuvant lead to significantly faster recovery than antigen alone (Fig 3G). 255 
There was a slight reduction in viral load in the group that received the highest dose of 256 
adjuvant (Fig 3H). There was very little effect on the influenza-specific CD8+ response in the 257 
lungs (Fig 3I) or airway IgA (Fig 3J). From these studies we conclude that NanoSiO2 was the 258 
most effective adjuvant of those screened. 259 
NanoSiO2 is an effective adjuvant in neonates 260 
The aim of the study was to develop a novel adjuvant that would be effective in early life. 261 
Neonatal (7 day old) mice were immunised intramuscularly with 0.1 μg H1N1 262 
haemagglutinin antigen alone or in combination with 50 μg NanoSiO2 as an adjuvant. The 263 
vaccine was delivered in two doses of 25 μl, one to each leg, because of the small muscle 264 
volume in seven day old mice. The inclusion of NanoSiO2 as an adjuvant significantly 265 
(p<0.05, Fig 4A) increased the anti-influenza IgG response in sera prior to an influenza 266 
infection 5 weeks later (week 6 of life). Neonatal mice receiving the adjuvanted vaccine 267 
were protected against infection, losing significantly less weight on days 5, 6 and 7 after 268 
infection (p<0.05, Fig 4B). There was a trend towards reduced influenza viral load in the 269 
group receiving NanoSiO2 adjuvanted vaccine (Fig 4C). H1-specific IgA measured in the 270 
airway was also significantly higher in the adjuvant group (p<0.05, Fig 4D). There was a slight 271 
increase in the percentage of influenza-specific CD8+ cells in the lungs of the mice receiving 272 
the adjuvant (Fig 4E). From this we conclude that NanoSiO2 is effective as an adjuvant in 273 
early life. 274 
Adjuvants cause local inflammatory cell recruitment to the muscle but not the lymph 275 
nodes, and no serum inflammation signal. 276 
Adjuvants can boost immune responses to vaccine antigens through a number of different 277 
mechanisms (26). These include depot effect and pattern recognition receptor activation 278 
(e.g. TLR or inflammasome) leading to immune cell recruitment, activation and the release 279 
of cytokines. We wanted to investigate the mechanism of the novel adjuvants. To explore 280 
the role of depot effect we measured some of the physical properties of NanoSiO2 and 281 
CPPD. Using light microscopy, we imaged suspensions of the two compounds that we used 282 
in the studies. NanaSiO2 was mainly small irregular dispersion (Fig 5A), whilst CPPD formed 283 
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longer, irregular, rod-shaped crystalline structures (Fig 5B). Since adjuvant activity can be 284 
linked to protein adsorption onto the particle, leading to a depot effect, we measured the 285 
amount of protein adsorbed to the particles. Adsorption of both proteins was quite low. 286 
Using bovine serum albumin (BSA) as a control protein, we observed a mean of 20% (+/- 5%) 287 
adsorption on to the NanoSiO2 particles and a mean of 25% (+/-7%) adsorption onto CPPD 288 
(Fig 5C). A similar level of adsorption, 35%, was seen when influenza antigens were used 289 
rather than BSA (data not shown).  290 
We wanted to examine the inflammatory effect of the adjuvants on the local/ immunised 291 
tissue. Mice were immunised intramuscularly with the top dose of each adjuvant used in the 292 
titration studies (50 μg NanoSiO2, 40 μg CPPD, 5 μg M-Tri-DAP) and this was compared to 293 
PBS alone to reflect tissue damage caused by the injection bolus. The adjuvant MF59 was 294 
used as a positive control. Serum was sampled at 12 and 24 hours after administration and 295 
inflammatory mediators measured by Luminex. As previously observed (27), MF59 induced 296 
CCL2 (Fig 5D), CXCL1 (Fig 5E) and IL-5 (Fig 5F) in the serum, however, whilst CPPD did induce 297 
some IL-1β in the serum at 12 hours after injection, there was no significant effect of the 298 
other adjuvants (Fig 5G). Injection appeared to induce IL-1α (Fig 5I) as all groups had a peak 299 
at 4 hours after immunisation that waned. There was no upregulation of GM-CSF, IL-12p70, 300 
CXCL2, VEGF, IL-10, CXCL10 or CCL3 in the sera relative to the PBS control after 301 
immunisation with the experimental adjuvants (data not shown). At 24 hours after injection, 302 
muscles were dissected and cells analysed by flow cytometry to measure which cells, 303 
defined as CD11b+, were entering the muscle (27). There was a significant influx of 304 
neutrophils (Ly6G+ cells) after injection of MF59 and CPPD (p<0.05, Fig 5I). Likewise there 305 
was a significant increase in macrophages (F4/80+ cells) in the muscle after MF59 injection 306 
(Fig 5J). Injection led to an increase in CD11c/ MHCII positive dendritic cells in all cases, but 307 
levels were only significantly greater after M-Tri-DAP injection (Fig 5K). NanoSiO2 led to a 308 
modest increase in all cell types but it was not significant. Immune cell activation was 309 
measured by expression of the surface marker CD80 (Fig 5L, M). There was a trend towards 310 
increased CD80 in muscle macrophages compared to PBS and significantly increased CD80 in 311 
DC after M-Tri-DAP immunisation. There was no detectable recruitment of neutrophils, 312 
macrophages or DC into the muscle draining lymph nodes after immunisation (data not 313 
shown).  314 
14 
 
The adjuvant effect of NanoSiO2 is partially dependent upon caspase 1, but independent 315 
of IL-1β. 316 
Having observed increased recruitment and activation of leukocytes to the injection site, we 317 
wished to define the process that led to their recruitment. The agents used in this study 318 
were selected because they have been proposed to activate the inflammasome and 319 
therefore might bypass the reduced functionality of TLR in early life. Therefore, we wished 320 
to determine whether the ability of the NanoSiO2 to boost the immune response was 321 
related to inflammasome function. To test this we blocked caspase 1, the major enzyme 322 
involved in the cleavage of pro-cytokines to their active forms, with the irreversible inhibitor 323 
YVAD, and also used an anti-IL-1β blocking antibody. Treatments were applied 324 
intraperitoneally on d-1 and d+1 of the immunisation. Anti-IL-1β treatment had no effect on 325 
the anti-H1N1 response compared to the untreated NanoSiO2 adjuvanted group (Fig 6A). 326 
The animals treated with YVAD lost more weight than the animals receiving NanoSiO2, 327 
though the loss of protection was not complete, as the YVAD group’s profile was between 328 
the adjuvanted and un-adjuvanted groups (Fig 6B). There was significantly less virus in all 329 
the adjuvanted groups than the unadjuvanted group (p<0.05, Fig 6C), but neither blocking 330 
treatment affected viral load. There was no effect of treatment on BAL IgA (Fig 6D) or 331 
influenza-specific CD8+ cells in the lung (Fig 6E). This suggests that the adjuvant effect of 332 
NanoSiO2 may be independent of the caspase/IL-1β axis. 333 
Discussion 334 
In these studies we tested a number of compounds, which have previously been described 335 
as inflammasome or NOD receptor agonists, for their ability to act as adjuvants. Of the 336 
compounds tested, we observed that NanoSiO2 was the most effective. Using NanoSiO2 as 337 
an adjuvant significantly boosted the humoral and cellular responses to influenza antigen, 338 
reducing weight loss following infection. The other agents tested in the pilot study (IE-DAP, 339 
MDP, MSU and alum crystals) had very little effect on the response, though it may be that 340 
we did not use an optimum dose, as titration of NanoSiO2 and M-Tri-DAP improved 341 
responses. It was of note that NanoSiO2 was an effective adjuvant when used in early life. 342 
When we investigated the potential mechanism of action of NanoSiO2, we observed that 343 
blocking IL-1β or Caspase 1 had minimal effect on the adjuvanticity. 344 
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A previous study used M-Tri-DAP in conjunction with Chlamydia trachomatis major outer 345 
membrane protein (MOMP), but with limited effect and no protection against intranasal 346 
Chlamydia challenge (28). The current study is the first that has explored the use of 347 
NanoSiO2 or CPPD as potential adjuvants. Inflammation caused by microparticles has been 348 
well-characterised and has previously been connected with inflammatory conditions such as 349 
Crohn’s disease (17). CPPD is the causal agent of pseudogout, which is associated with IL-1β, 350 
and CPPD was the only adjuvant that induced systemic IL-1β after administration. One 351 
consideration with the two inorganic, microparticle compounds used in this study is 352 
biodistribution and elimination after immunisation. Studies suggest that most particles are 353 
retained in the injection site, which may be important if they are acting as a depot, whilst 354 
some cross into the liver and they are excreted through urine and faeces (29). The length of 355 
time in the body and biodistribution of these compounds may lead to systemic effects, but 356 
we observed little systemic signals of inflammation after immunisation. 357 
The main aim of this study was to develop adjuvants that are effective in early life. We have 358 
recently demonstrated that MF59 is highly effective in juvenile animals (3 weeks old) and 359 
MF59 has also been shown to improve immunogenicity in children over 6 months old (30), 360 
but it had limited efficacy in 1 week old mice and has not been tested in younger infants. In 361 
the current study, we demonstrated that NanoSiO2 was effective in early life, leading to a 362 
significant reduction in disease following infection compared to antigen alone. A recent 363 
study using a polysaccharide microparticle adjuvant (Advax) also demonstrated protection 364 
against influenza challenge (31); likewise, an alphavirus based adjuvant improved protection 365 
compared to antigen alone (32). It is of note that all these formulations are microparticle 366 
based, though it is not clear how the particles are being recognised by the immune system 367 
as studies have suggested IL-1β responses in early life are deficient (33), however, this may 368 
be dependent upon the agonist used (34). 369 
Mechanistically, it has been suggested that microparticles including NanoSiO2 activate the 370 
NLRP3 inflammasome via ATP, ADP and adenosine (16). Whilst in vitro we observed IL-1β 371 
after exposure to NanoSiO2 in a macrophage-like cell line, in vivo we observed very little 372 
circulating IL-1β in the serum at acute time points after immunisation. Blockade of IL-1β and 373 
caspase 1 had limited effect on the adjuvant activity of NanoSiO2. The measurement of 374 
cytokines in the serum may not fully reflect the situation at the site of injection; however, as 375 
16 
 
seen in previous studies (25) MF59 did induce an acute wave of CCL2, CXCL1 and IL-5. The 376 
treatment regime used for the IL-1β blockade or YVAD treatment may have led to 377 
incomplete blockade of the inflammasome, though in previous studies blocking IL-1β with 378 
the same protocol significantly altered the immune response to viral infection (35) and in 379 
vivo YVAD treatment has been shown to reduce IL-1β in the lungs (36). Studies suggest a 380 
role for activation of autophagy pathways by NanoSiO2 which may trigger an inflammation 381 
independently of Caspase 1 (37). More research is required to confirm the mechanism of 382 
these agents, especially in early life. However, whilst the mechanism of NanoSiO2 action is 383 
unclear, this work supports the approach of targeting other danger sensing pathways for 384 
neonatal adjuvants. 385 
The balance between safety/reactogenicity and immunogenicity in adjuvants is an 386 
important consideration and more research is required on the biomarkers of vaccine safety 387 
(38). Safety concerns may also be different in early life compared to adults, for example the 388 
AS03 adjuvanted influenza vaccine was associated with narcolepsy in European children 389 
(39), but not in adults. It may be that adverse events present differently in the different 390 
ages: the 2010 split vaccine manufactured by CSL (Fluvax) was associated with febrile 391 
convulsions (4.4 per 1,000 doses) in children (40) but not in adults, even though it induced 392 
more local reactions in adults than an equivalent vaccine from another manufacturer (41).  393 
Due to the relatively more straightforward regulatory process, current discussions about 394 
protecting neonates from infection are focussed on the benefits of improving coverage of 395 
influenza vaccination in mothers and then using catch-up immunisation in older children. 396 
This may limit clinical development of neonate-specific approaches, but the demonstration 397 
that a broad class of compounds, microparticles, have inflammatory effect in infancy is an 398 
important finding and may shape future research in the development of vaccines for infancy 399 
specific diseases such as RSV, where the lack of direct benefit to the mother of the 400 
immunisation (as compared to influenza) may change the regulatory space. 401 
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Figure 1. Screening inflammasome inducing compounds for IL-1β inducing activity and 544 
adjuvant effect. Following differentiation into macrophage-like cells via PMA incubation, 545 
THP-1 cells were seeded into wells of a 24-well tissue culture plate and incubated with 10 546 
μg/ml inflammasome and NOD ligands. Supernatants were sampled at 24, 48 and 72 hours 547 
and analysed for IL-1β content by ELISA (A). Bone marrow derived macrophages were pre-548 
exposed to 1 μg MPLA for 2 hours prior to exposure to putative adjuvants and IL-1β 549 
responses measured (B). CB6F1 adult female mice were immunised i.m. with 0.1 μg dose of 550 
H1N1 antigen with or without adjuvant candidates or control treatments. Mice were 551 
challenged 4 weeks after immunisations with 6x104 PFU H1N1 Eng 195 influenza and 552 
monitored for weight loss before harvest on day 7. Weight change during influenza infection 553 
(C). D7 weights (D). Serum anti-H1N1 IgG (E) and BAL fluid anti-H1N1 IgA (F) on day 7 post-554 
infection. Points (A,B) represents mean of n= 3 studies *** p<0.001 comparing NanoSiO2 555 
and control, points (C) bars, (D) and lines (E, F) represent mean of n=3 mice. 556 
Figure 2. Dose titration of NanoSiO2. Adult female CB6F1 mice were immunised i.m. with 557 
0.1 μg H1N1 HA antigen alone, in combination with 1, 10 or 50 μg dose of NanoSiO2. 4 558 
weeks later, mice were infected i.n. with influenza. Serum anti-H1N1 IgG levels were 559 
assessed before (A) infection. Weight change during H1N1 infection (B). Influenza M gene 560 
RNA levels in lung on d7 after infection (C). BAL fluid anti-H1N1 IgA (D) on day 7 after 561 
infection. CD8+ cells specific for H1 influenza by FACS (E). Correlation of day 7 serum anti-562 
H1N1 IgG (F), BAL anti-H1N1 IgA (G) and influenza-specific proportion of CD8+ cells (H) to 563 
day 7 infection weight loss %. Points (A) and lines (A, C-E) represent mean of n≥4 mice. 564 
*p<0.05 and **p<0.01 measured by one or two-way ANOVA. G, H, I correlation by Pearson r 565 
test. 566 
Figure 3. Dose titration of CPPD and M-Tri-DAP. Adult female CB6F1 mice were immunised 567 
i.m. with 0.1 μg H1N1 antigen alone, in combination with either 2.5, 10 or 40 μg dose of 568 
CPPD (A-E) or a 0.05, 0.5 or 5 μg dose of M-Tri-DAP (F-J) prior to infection with H1N1 569 
influenza. Serum anti-H1N1 IgG levels were assessed before (A, E) infection. Mice were 570 
monitored for weight changes during infection (B, G). Influenza M gene RNA levels (C, H), 571 
CD8+ cells specific for influenza (D, I) in lung and BAL anti-H1N1 (E, J) on d7 after infection. 572 
Lines and points represent mean of n≥4 mice *p<0.05, **p<0.01 measured by one way (A) 573 
or two-way ANOVA (G). 574 
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Figure 4. Nano SiO2 is effective in early life. Seven day old CB6F1 mice were immunised i.m. 575 
with 0.1 μg H1N1 antigen alone or in combination with 50μg dose of Nano SiO2. 5 weeks 576 
later, mice were infected intranasally with H1N1 as adults. Serum anti-H1N1 IgG levels were 577 
assessed before infection (A). Weight change after infection (B). Lung viral load (C), BAL IgA 578 
(D) and CD8+ cells specific for influenza (E) were measured on d7 after infection . Lines (A, C-579 
E) and points (B) represent means of n≥6 mice. *p<0.05 and ***p<0.001 measured by two-580 
way ANOVA (B) or t-tests (A, C). 581 
Figure 5. Properties of microparticle adjuvants and effect on immune response. Light 582 
microscopic imaging of suspensions of NanoSiO2 (A) or CPPD (B). Analysis of protein 583 
adsorption by microparticles (C). Lines represent means of n=4 studies. Adult female CB6F1 584 
mice were administered PBS, 1μg MPLA, MF59, 40 μg CPPD or 5 μg M-Tri-DAP i.m. in a 50 μl 585 
volume in the right hind quadriceps muscle. Serum was sampled at 4, 12 and 24 hours after 586 
injection and serum CCL2 (D), CXCL1 (E), IL-5 (F), IL-1β (G) and IL-1α (H) analysed by 587 
Luminex. Mice were culled for harvest at 24 hours and injected muscles were excised and 588 
digested into a single cell suspension for analysis by flow cytometry. Live cells were stained 589 
for CD11b and Ly6G (I), F4/80 (J), CD11c/MHCII (K). % CD80 on F4/80 (L) and CD11c cells (M) 590 
measured by flow cytometry. Lines (A-D) represent mean of n=5 mice and points represent 591 
individual animals (E-G). *p<0.05, **p<0.001 measured by Kruskal Wallis test. 592 
Figure 6. Effect of inflammasome blocking reagents on adjuvanticity of NanoSiO2. Adult 593 
female CB6F1 mice were immunised i.m. with 0.1 μg H1N1 antigen in combination with 50 594 
μg dose of NanoSiO2 and were treated with either 0.5 mg anti-mIL-1β antibody i.p. or 595 
10mg/kg caspase-1 inhibitor (YVAD) i.p. 24 hours before and after immunisations, effects 596 
were compared to mice receiving antigen alone or antigen and adjuvant. 4 weeks later, mice 597 
were infected i.n. with H1N1 influenza. Serum anti-influenza IgG was assessed 1 day before 598 
(A). Weight change during influenza infection (B). Viral load (C), BAL anti-influenza IgA (D) 599 
influenza specific CD8+ T cells (F) on day 7 of infection. Points (B) and lines (A, C-E) represent 600 
mean of n=5 mice. *p<0.05, **p<0.01 NanoSiO2 vs Antigen Alone as measured by two-way 601 
ANOVA. 602 






